A Better Test for Kidney Disease
More than 37 million people in the U.S. are living with chronic kidney disease, or CKD. In this condition, the kidneys can’t filter blood the way they should. CKD may eventually lead to kidney failure.
The most common blood test for CKD measures a protein called creatinine. Doctors use the amount of creatinine to estimate kidney function. This can affect the timing of treatments. Delaying treatment may lead to worse kidney health outcomes.
Black Americans generally have higher amounts of creatinine. The reasons for this aren’t understood. Formulas for kidney function take these differences into account. This helps improve the accuracy of the test for Black Americans.
However, there’s a lot of diversity among self-reported racial groups, which are not based on biology. Race encompasses broad groups of people with different backgrounds and ancestry. Using race in kidney function formulas can lead to inaccurate classification for some people with CKD.
Researchers looked at whether they could use a different protein to estimate kidney function, cystatin C. This protein showed similar levels in nonblack and Black study participants. The study found that using cystatin C levels to estimate kidney function improved accuracy when race was not included.
The addition of cystatin C may help reduce racial bias and errors in classifying chronic kidney disease.
“An accurate kidney function formula that does not rely on self-reported race is a huge leap forward for all people with, and at risk for, chronic kidney disease,” says NIDDK Director Dr. Griffin P. Rodgers.
NIH Office of Communications and Public Liaison
Building 31, Room 5B52
Bethesda, MD 20892-2094
Editor: Harrison Wein, Ph.D.
Managing Editor: Tianna Hicklin, Ph.D.
Illustrator: Alan Defibaugh
Attention Editors: Reprint our articles and illustrations in your own publication. Our material is not copyrighted. Please acknowledge NIH News in Health as the source and send us a copy.